Another thing to look at here is something that's a little mis-understated is CPI-300 wasn't the ONLY thing going on with IGXT (even though most here have no clue)
Par Pharmaceuticals and the development agreement with them. I can't find any information on value, but I'm sure Par Pharma will pay big $$$ for co-development of a drug using Intelgenx's delivery methods ($$$). It's listed on PRX's 8k, but not stated what IntelGenx has received and/or will receive. This could be HUGE as Par Pharma is a pretty big Pharmaceutical (see NYSE PRX)!
12/16/11 Par Pharma filed a CT filing (Confidential Treatment) - a few days later IGXT comes out with Par Pharma co-development on a drug with terms undisclosed. Is it possible IGXT signed with Edgewater Pharmaceuticals because CPI-300 is small fish compared to the confidential agreement with Par Pharma and CPI-300 as long as it gives "something" is good enough ?
1/6/12 Par Pharma filed an 8k listing IntelGenx as co-developer
See page 43 - IntelGenx Dev Deal for 2011
Per IGXT's 8k regarding PAR Pharmaceuticals on 12/21/11
Item 1.01 Entry Into a Material Definitive Agreement.
On December 19, 2011, IntelGenx Corp., a wholly owned subsidiary of IntelGenx Technologies Corp. (the “Company”), entered into a Development Services and Commercialization Agreement (the “Agreement”) with Par Pharmaceutical, Inc. (“Par”) for the development and commercialization of a new product utilizing one of the Company’s proprietary oral drug delivery platforms.
Under the terms of the Agreement, Par has obtained certain exclusive rights to market and sell the product in the United States. In exchange for granting Par such rights, the Company will receive upfront payments, contingent milestone payments, and a double-digit percentage royalty of all net sales upon commercialization. In addition, Par has a right of first refusal to obtain the exclusive commercialization rights for an additional new product utilizing one of the Company’s proprietary drug delivery platforms.
The term of the agreement is the later of (i) 10 years following the earlier of commercial launch and the first commercial sale of the product; and (ii) the end of the commercial life of the product, unless otherwise terminated in the event of, without limitation (i) failure by either the Company or Par to perform their respective obligations under the Agreement; (ii) if pilot bioequivalency studies are not successful, or (iii) otherwise by mutual consent of the parties. The Agreement also contains customary confidentiality, indemnification and intellectual property protection provisions.
On December 21, 2011, the Company issued a press release announcing entry into the Agreement, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
This is ONLY one... There are many more things going on at IGXT as this will be BIG in 2013 !!
